Literature DB >> 23589410

Barriers to mental health care utilization in Parkinson's disease.

Roseanne D Dobkin1, Jade Tiu Rubino, Jill Friedman, Lesley A Allen, Michael A Gara, Matthew Menza.   

Abstract

BACKGROUND: Parkinson's disease (PD) is frequently complicated by co-occurring psychiatric problems such as depression and anxiety that negatively affect the course and management of the illness. Yet, in most cases, these psychiatric comorbidities are neither recognized nor treated to remission. The primary purpose of this study was to identify and describe barriers to mental health care utilization for people with PD. Secondary objectives included the assessment of attitudes and preferences regarding the need for mental health services in the PD community and the acceptability of telehealth interventions as a method for improving access and quality of care.
METHODS: A total of 769 people with PD completed an anonymous cross-sectional questionnaire assessing barriers to mental health care utilization in this medical population. Respondents were drawn from a national sample.
RESULTS: Commonly endorsed barriers to mental health care utilization in PD reflect the patients' incomplete understanding of mental health problems, access issues, and illness-specific concerns, as well as the inadequate screening and detection of psychiatric complications by medical providers and the need for more effective treatments in this medical population. Several demographic, medical, and psychiatric variables also influenced the likelihood of accessing mental health care. Interest in telehealth approaches to mental health treatment was high and, in several instances, correlated with perceived barriers to mental health care utilization.
CONCLUSIONS: People with PD may encounter a multitude of barriers that impede their pursuit of mental health care. Clinical implications are discussed and further research is needed to replicate and extend these findings.

Entities:  

Keywords:  Parkinson’s disease; anxiety; barriers; depression; mental health care utilization

Mesh:

Year:  2013        PMID: 23589410      PMCID: PMC3644337          DOI: 10.1177/0891988713481269

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  19 in total

1.  Increasing access to specialty care: a pilot, randomized controlled trial of telemedicine for Parkinson's disease.

Authors:  E Ray Dorsey; Lisa M Deuel; Tiffini S Voss; Kara Finnigan; Benjamin P George; Sheelah Eason; David Miller; Jason I Reminick; Anna Appler; Joyce Polanowicz; Lucy Viti; Sandy Smith; Anthony Joseph; Kevin M Biglan
Journal:  Mov Disord       Date:  2010-08-15       Impact factor: 10.338

2.  Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial.

Authors:  Roseanne D Dobkin; Matthew Menza; Lesley A Allen; Michael A Gara; Margery H Mark; Jade Tiu; Karina L Bienfait; Jill Friedman
Journal:  Am J Psychiatry       Date:  2011-06-15       Impact factor: 18.112

3.  Non-recognition of depression and other non-motor symptoms in Parkinson's disease.

Authors:  L M Shulman; R L Taback; A A Rabinstein; W J Weiner
Journal:  Parkinsonism Relat Disord       Date:  2002-01       Impact factor: 4.891

4.  Effect of telephone-administered vs face-to-face cognitive behavioral therapy on adherence to therapy and depression outcomes among primary care patients: a randomized trial.

Authors:  David C Mohr; Joyce Ho; Jenna Duffecy; Douglas Reifler; Leslie Sokol; Michelle Nicole Burns; Ling Jin; Juned Siddique
Journal:  JAMA       Date:  2012-06-06       Impact factor: 56.272

5.  Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis.

Authors:  D C Mohr; W Likosky; A Bertagnolli; D E Goodkin; J Van Der Wende; P Dwyer; L P Dick
Journal:  J Consult Clin Psychol       Date:  2000-04

6.  Telephone-based cognitive-behavioral therapy for depression in Parkinson disease.

Authors:  Roseanne D Dobkin; Matthew Menza; Lesley A Allen; Jade Tiu; Jill Friedman; Karina L Bienfait; Michael A Gara; Margery H Mark
Journal:  J Geriatr Psychiatry Neurol       Date:  2011-12       Impact factor: 2.680

7.  A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.

Authors:  I H Richard; M P McDermott; R Kurlan; J M Lyness; P G Como; N Pearson; S A Factor; J Juncos; C Serrano Ramos; M Brodsky; C Manning; L Marsh; L Shulman; H H Fernandez; K J Black; M Panisset; C W Christine; W Jiang; C Singer; S Horn; R Pfeiffer; D Rottenberg; J Slevin; L Elmer; D Press; H C Hyson; W McDonald
Journal:  Neurology       Date:  2012-04-11       Impact factor: 9.910

8.  Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia.

Authors:  Jaime Kulisevsky; Javier Pagonabarraga; Berta Pascual-Sedano; Carmen García-Sánchez; Alexandre Gironell
Journal:  Mov Disord       Date:  2008-10-15       Impact factor: 10.338

9.  Recognition and treatment of depression in Parkinson's disease.

Authors:  Daniel Weintraub; Paul J Moberg; John E Duda; Ira R Katz; Matthew B Stern
Journal:  J Geriatr Psychiatry Neurol       Date:  2003-09       Impact factor: 2.680

10.  Barriers to healthcare utilization in fatiguing illness: a population-based study in Georgia.

Authors:  Jin-Mann S Lin; Dana J Brimmer; Roumiana S Boneva; James F Jones; William C Reeves
Journal:  BMC Health Serv Res       Date:  2009-01-20       Impact factor: 2.655

View more
  15 in total

Review 1.  Psychiatric issues in cognitive impairment.

Authors:  Dag Aarsland; John-Paul Taylor; Daniel Weintraub
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

2.  Getting to More Effective Weight Management in Antipsychotic-Treated Youth: A Survey of Barriers and Preferences.

Authors:  Ginger Nicol; Elizabeth Worsham; Debra Haire-Joshu; Alexis Duncan; Julia Schweiger; Michael Yingling; Eric Lenze
Journal:  Child Obes       Date:  2016-01-20       Impact factor: 2.992

Review 3.  Depression and Parkinson's disease: current knowledge.

Authors:  Laura Marsh
Journal:  Curr Neurol Neurosci Rep       Date:  2013-12       Impact factor: 5.081

4.  Annual Prevalence of Use of Potentially Inappropriate Medications for Treatment of Affective Disorders in Parkinson's Disease.

Authors:  Danielle S Abraham; Thanh Phuong Pham Nguyen; Sean Hennessy; Shelly L Gray; Dawei Xie; Daniel Weintraub; Allison W Willis
Journal:  Am J Geriatr Psychiatry       Date:  2020-05-18       Impact factor: 4.105

5.  Cognitive behavioral therapy for depression in Japanese Parkinson's disease patients: a pilot study.

Authors:  Issei Shinmei; Kei Kobayashi; Yuki Oe; Yuriko Takagishi; Ayako Kanie; Masaya Ito; Yoshitake Takebayashi; Miho Murata; Masaru Horikoshi; Roseanne D Dobkin
Journal:  Neuropsychiatr Dis Treat       Date:  2016-06-08       Impact factor: 2.570

Review 6.  Neuropsychiatric symptoms in untreated Parkinson's disease.

Authors:  Szabolcs Szatmari; Ben Min-Woo Illigens; Timo Siepmann; Alexandra Pinter; Annamaria Takats; Daniel Bereczki
Journal:  Neuropsychiatr Dis Treat       Date:  2017-03-16       Impact factor: 2.570

7.  A waitlist-controlled trial of group cognitive behavioural therapy for depression and anxiety in Parkinson's disease.

Authors:  Lakkhina Troeung; Sarah J Egan; Natalie Gasson
Journal:  BMC Psychiatry       Date:  2014-01-27       Impact factor: 3.630

8.  Rumination and behavioural factors in Parkinson's disease depression.

Authors:  Camille L Julien; Katharine A Rimes; Richard G Brown
Journal:  J Psychosom Res       Date:  2016-01-30       Impact factor: 3.006

9.  Anxiety and anxious-depression in Parkinson's disease over a 4-year period: a latent transition analysis.

Authors:  S Landau; V Harris; D J Burn; J V Hindle; C S Hurt; M Samuel; K C Wilson; R G Brown
Journal:  Psychol Med       Date:  2015-10-23       Impact factor: 7.723

10.  Telephone-based cognitive behavioral therapy for depression in Parkinson disease: A randomized controlled trial.

Authors:  Roseanne D Dobkin; Sarah L Mann; Michael A Gara; Alejandro Interian; Kailyn M Rodriguez; Matthew Menza
Journal:  Neurology       Date:  2020-04-01       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.